Clinical Trials Directory

Trials / Conditions / Cancer of Prostate

Cancer of Prostate

43 registered clinical trials studyying Cancer of Prostate14 currently recruiting.

StatusTrialSponsorPhase
RecruitingPsilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
NCT07072728
Psyence Australia Pty LtdPhase 2
RecruitingInvestigation of Three Biomarkers for the Detection of Prostate Cancer
NCT06554587
Medtechtomarket Consulting Ltd
RecruitingThe Impact of Physical Activity Versus Dietary Energy Restriction on Tumour and Muscle Protein Synthesis in Pr
NCT06406803
Maastricht University Medical CenterN/A
RecruitingNeoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
NCT04887935
Washington University School of MedicinePhase 1
RecruitingImproving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Can
NCT05600400
Sunnybrook Health Sciences CentreN/A
RecruitingARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prosta
NCT05653063
University College, London
RecruitingA Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combinatio
NCT05361798
National Cancer Institute (NCI)Phase 2
Enrolling By InvitationReal-time Motion Management During Prostate and Lung Radiotherapy
NCT05844761
Region SkaneN/A
WithdrawnStudy of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
NCT05191017
Nuvation Bio Inc.Phase 1 / Phase 2
RecruitingArtificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention
NCT06318559
Fondazione del Piemonte per l'OncologiaN/A
TerminatedNUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid
NCT05252390
Nuvation Bio Inc.Phase 1
RecruitingA Intervention for Reducing Sedentary Behaviour Among Prostate Cancer Survivors
NCT05214937
University of TorontoN/A
UnknownRetzius-sparing Technique in Robotic-assisted Radical Prostatectomy
NCT05224024
Ankara UniversityN/A
Active Not RecruitingOnco-primary Care Networking to Support TEAM-based Care
NCT04258813
Duke UniversityN/A
Active Not RecruitingDarolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
NCT04319783
Trans Tasman Radiation Oncology GroupPhase 2
RecruitingA Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive a
NCT04633252
National Cancer Institute (NCI)Phase 1 / Phase 2
TerminatedStudy of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
NCT04541225
Nuvation Bio Inc.Phase 1
CompletedTailored, wEb-based, Psychosocial and Physical Activity Self-Management PrOgramme
NCT04304196
St. Mary's Research Center, CanadaN/A
TerminatedHypertension Management in Cancer Patients
NCT03919214
Duke UniversityN/A
UnknownRadiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence Afte
NCT03899077
Cancer Research AntwerpPhase 2
UnknownThe PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor
NCT03896958
SpeciCare
CompletedDe-implementation of Low Value Castration for Men With Prostate Cancer
NCT03579680
University of MichiganN/A
CompletedFeasibility Study Testing a Sleep Intervention in Prostate Cancer Patients With Insomnia
NCT03444532
Danish Cancer SocietyN/A
RecruitingProfiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
NCT03354416
National Cancer Institute (NCI)
CompletedHighly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
NCT03388619
National Cancer Institute (NCI)Phase 1
CompletedA Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer
NCT03450109
Luye Pharma Group Ltd.Phase 1
Enrolling By Invitation18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
NCT03181867
National Cancer Institute (NCI)Phase 2
CompletedPain Comparison Whit Visual Analog Scale (EVA) Between Four Analgesic Methods During Trans Rectal Prostatic Bi
NCT03442075
Instituto Mexicano del Seguro Social
CompletedRadiotherapy Assessments During Intervention ANd Treatment (RADIANT)
NCT03133286
DxTerity Diagnostics
CompletedClinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)
NCT03031418
Exosome Diagnostics, Inc.
CompletedOptimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors
NCT02957357
Alliance Foundation Trials, LLC.
CompletedBicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patie
NCT02614859
Fox Chase Cancer CenterPhase 2
CompletedLong-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previou
NCT02362464
National Cancer Institute (NCI)Phase 2
CompletedProstatic Cancer Versus Androgen Deficiency
NCT02235142
Hopital FochN/A
CompletedSipuleucel-T Manufacturing Demonstration Study
NCT01477749
DendreonPhase 2
CompletedAssessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci
NCT01639859
Hospices Civils de LyonN/A
UnknownDynamic Focusing Evaluation for Prostate Cancer Treatment
NCT03632980
EDAP TMS S.A.N/A
CompletedNorth Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)
NCT02564120
UNC Lineberger Comprehensive Cancer Center
TerminatedStudy to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator
NCT00999960
Assistance Publique - Hôpitaux de ParisN/A
CompletedDendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Abl
NCT00970203
Roswell Park Cancer InstitutePhase 2
RecruitingCollection of Blood From Patients With Prostate Cancer
NCT00923221
National Cancer Institute (NCI)
CompletedA Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Sw
NCT00220194
San Bernardino Urological Associates Medical Group IncPhase 4
CompletedA Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Che
NCT00257478
Astellas Pharma IncPhase 2